Safety and Efficacy Study of the Trifunctional Antibody Ertumaxomab to Treat Patients With Advanced or Metastatic Breast Cancer

• Status: Terminated
• Trial end date: 2009-02-01

Summary

The purpose of this study is to determine the safety and efficacy of the investigational trifunctional anti-Her-2/neu x anti-CD3 antibody ertumaxomab as treatment for hormone therapy refractory Her-2/neu 1+ or 2+ expressing advanced or metastatic breast cancer

• Phase: Phase 2

Details

• Lead Sponsor: Neovii Biotech
• Treatments: Antibodies; Antibodies, Monoclonal